[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:pleomorphic-liposarcoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":29,"states":30},"Pleomorphic Liposarcoma",3,[7,15,22],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06239272","NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)",[11],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:06.247899Z","2026-07-19T19:36:05.068230Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT07089992","A Study of Pembrolizumab in People With Ultra-Rare Sarcomas",[19],"Phase 2","2026-08-26T02:16:48.735701Z","2026-07-05T05:32:16.733886Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":27,"content_modified":28},"NCT06113809","Palbociclib and Pembrolizumab in Sarcoma",[26],"Phase 1","2026-08-26T02:17:39.857430Z","2026-05-05T02:35:31.898243Z",[],[]]